Turning groundbreaking research from the Institut Pasteur with the support of Argobio's start-up studio, into novel treatments for cancer, inflammatory diseases and viral infections. The platform ...
AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a ...
The previously-unknown condition, dubbed 'post-vaccination syndrome' (PVS), can persist years after taking the jabs - made by ...
Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...
Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...
Stillman College is the recipient of a $250,000 grant from Pfizer. The Multicultural Health Equity Collective will support ...
Researchers at the Wuhan Institute of Virology in China said they discovered a new coronavirus in bats that enters cells ...
There are steps we can take to protect Floridians from the bird flu epidemic, says World Health Organization expert | Opinion ...
Bernstein lowered the firm’s price target on Pfizer (PFE) to $30 from $32 and keeps a Market Perform rating on the shares. The firm notes ...
Parents of a girl from Cleveland say a recent Super Bowl ad from Pfizer gives the wrong idea about childhood cancer treatment.We've told you about Olivia Weathe ...
With Mayne Pharma subject to a $670 million takeover offer, investor attention turns to who might be acquired next.
Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results